Ayami Kaneko

Lactate dehydrogenase-to-lymphocyte ratio predicts overall and progression-free survival among patients with advanced small-cell lung cancer receiving first-line chemoimmunotherapy

Tomofumi Hirose, Shuhei Teranishi, Nobuaki Kobayashi, Anna Tanaka et autres

Platinum plus etoposide combined with programmed death-ligand 1 (PD-L1) inhibitors is the standard first-line therapy for patients with advanced small-cell lung cancer (SCLC). However, reliable prognostic biomarkers are yet to be identified. The lactate dehydrogenase-to-lymphocyte ratio (LLR) is a potential indicator of …

jp (code pays fourni par la source)

Nab-paclitaxel or Paclitaxel Treatment for Relapsed Small Cell Lung Cancer: A Single-arm Meta-analysis

Sousuke Kubo, Kohei Somekawa, Satoshi Nagaoka, Sachiko Matsumoto et autres

Background/Aim: Relapsed small cell lung cancer (SCLC) treatment has limited evidence-based options. Solvent-based paclitaxel (PTX) and albumin-bound nanoparticle paclitaxel (nab-PTX) are commonly prescribed though never comprehensively quantified. Patients and Methods: A systematic review and single-arm meta-analysis was conducted (PROSPERO Registration: CRD42024592475). PubMed, …

jp, cn (code pays fourni par la source)

189eP Regulation of PD-L1 expression by miR–200 family in non-small cell lung cancer

Ayami Kaneko, N. Kobayashi, K. Somekawa, S. Kubo et autres

jp (code pays fourni par la source)

1019P High-sensitivity and rapid detection of driver mutations in non-small cell lung cancer using droplet digital PCR analysis of bronchial wash fluid

K. Somekawa, N. Kobayashi, Yukihito Kajita, Suguru Muraoka et autres

jp (code pays fourni par la source)

The miR-200 Family in Non-Small-Cell Lung Cancer: Molecular Mechanisms, Clinical Applications, and Therapeutic Implications

Nobuaki Kobayashi, Yukihito Kajita, Fangfei Yang, Nobuhiko Fukuda et autres

Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide, demanding improved biomarkers and therapeutic approaches. This review synthesizes the extensive evidence positioning the miR-200 family as a master regulator of NSCLC progression. We detail the core molecular circuitry centered …

jp (code pays fourni par la source)

Valid surrogate end-points in nonsmall cell lung cancer peri-operative systemic therapy trials: a systematic review

Kohei Somekawa, Nobuyuki Horita, Satoshi Nagaoka, Yukihito Kajita et autres

BACKGROUND: Recurrence-, progression-, disease- and event-free survival are often selected as the primary end-points for trials assessing peri-operative systemic therapy for nonsmall cell lung cancer (NSCLC). As overall survival (OS) has increased, these surrogates, which we hereafter collectively term "recurrence-/progression-free survivals (RPFS)", …

jp (code pays fourni par la source)

Real-world efficacy of immune checkpoint inhibitors in PD-L1 negative non-small cell lung cancer: a multicenter retrospective study

Suguru Muraoka, Nobuaki Kobayashi, Ayami Kaneko, Kohei Somekawa et autres

Background: chemotherapy alone in PD-L1 negative NSCLC patients. Methods: This multicenter, retrospective study analyzed advanced or recurrent NSCLC patients treated between 2015 and 2022 in Japan. From an initial screening of 1,382 patients, we identified patients with PD-L1 negative [tumor proportion score …

jp, us (code pays fourni par la source)

MiR-200a regulates PD-L1 and predicts response to immune checkpoint inhibitors in advanced non-small cell lung cancer

Ayami Kaneko, Nobuaki Kobayashi, Sousuke Kubo, Satoshi Nagaoka et autres

Background: The microRNA (miR)-200 family is implicated in regulating the immune checkpoint protein programmed death-ligand 1 (PD-L1), a key factor in lung cancer progression and response to immunotherapy. This study investigates the relationship between miR-200 expression and PD-L1 in non-small cell lung …

jp, us (code pays fourni par la source)

Rapid detection of non-small cell lung cancer driver mutations using droplet digital polymerase chain reaction analysis of bronchial washings: a prospective multicenter study

Kohei Somekawa, Nobuaki Kobayashi, Satoshi Nagaoka, Kenichi Seki et autres

Background: Molecular profiling of non-small cell lung cancer (NSCLC) is crucial for personalized treatment, but obtaining adequate tumor tissue can be challenging. This study evaluated the utility of droplet digital polymerase chain reaction (ddPCR) analysis of bronchial washings (BWs) and serum for …

jp (code pays fourni par la source)

The Impact of Bevacizumab and miR200c on EMT and EGFR-TKI Resistance in EGFR-Mutant Lung Cancer Organoids

Nobuaki Kobayashi, Seigo Katakura, Nobuhiko Fukuda, Kohei Somekawa et autres

Objectives: This research aims to investigate the mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC), particularly focusing on the role of the epithelial–mesenchymal transition (EMT) within the tumor microenvironment (TME). Materials and Methods: …

jp (code pays fourni par la source)

Total baseline tumor size predicts survival among patients with advanced small-cell lung cancer receiving chemotherapy plus programmed death-ligand 1 inhibitor as first-line therapy: a multicenter retrospective observational study

Anna Tanaka, Shuhei Teranishi, Yukihito Kajita, Tomofumi Hirose et autres

Introduction: Total baseline tumor size (BTS) is a prognostic factor for programmed death 1 and programmed death-ligand 1 (PD-L1) inhibitor treatments. However, the prognostic value of total BTS for patients with small-cell lung cancer (SCLC) who receive chemotherapy plus PD-L1 inhibitor remains …

jp (code pays fourni par la source)

High red blood cell distribution width attenuates the effectiveness of Immune checkpoint inhibitor therapy: An exploratory study using a clinical data warehouse

Hiromi Matsumoto, Taichi Fukushima, Nobuaki Kobayashi, Yuuki Higashino et autres

BACKGROUND: Immune checkpoint inhibitors (ICIs) have improved outcomes in cancer treatment but are also associated with adverse events and financial burdens. Identifying accurate biomarkers is crucial for determining which patients are likely to benefit from ICIs. Current markers, such as PD-L1 expression …

jp (code pays fourni par la source)